<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37356024</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany.</ArticleTitle><Pagination><StartPage>4922</StartPage><EndPage>4938</EndPage><MedlinePgn>4922-4938</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11811-1</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Motor Neuron Diseases (MND) are rare diseases but have a high impact on affected individuals and society. This study aims to perform an economic evaluation of MND in Germany.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Primary patient-reported data were collected including individual impairment, the use of medical and non-medical resources, and self-rated Health-Related Quality of Life (HRQoL). Annual socio-economic costs per year as well as Quality-Adjusted Life Years (QALYs) were calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">404 patients with a diagnosis of Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) or Hereditary Spastic Paraplegia (HSP) were enrolled. Total annual costs per patient were estimated at 83,060&#x20ac; in ALS, 206,856&#x20ac; in SMA and 27,074&#x20ac; in HSP. The main cost drivers were informal care (all MND) and disease-modifying treatments (SMA). Self-reported HRQoL was best in patients with HSP (mean EuroQoL Five Dimension Five Level (EQ-5D-5L) index value 0.67) and lowest in SMA patients (mean EQ-5D-5L index value 0.39). QALYs for patients with ALS were estimated to be 1.89 QALYs, 23.08 for patients with HSP and 14.97 for patients with SMA, respectively. Cost-utilities were estimated as follows: 138,960&#x20ac;/QALY for ALS, 525,033&#x20ac;/QALY for SMA, and 49,573&#x20ac;/QALY for HSP. The main predictors of the high cost of illness and low HRQoL were disease progression and loss of individual autonomy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As loss of individual autonomy was the main cost predictor, therapeutic and supportive measures to maintain this autonomy may contribute to reducing high personal burden and also long-term costs, e.g., care dependency and absenteeism from work.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heinrich</LastName><ForeName>Felix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0007-0981-6486</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordts</LastName><ForeName>Isabell</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2078-1997</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts Der Isar, Technical University of Munich, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0329-5644</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, 01307, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stolte</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2774-067X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Medicine Essen, 45147, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeller</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3393-5657</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of W&#xfc;rzburg, 97080, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;ter</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hoher Mei&#xdf;ner Clinic, Neurology, 37242, Bad Sooden-Allendorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weyen</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ruhr-University Bochum, BG-Kliniken Bergmannsheil, 44789, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regensburger</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2172-7386</Identifier><AffiliationInfo><Affiliation>Department of Molecular Neurology, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, 91054, Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Rare Diseases Erlangen (ZSEER), University Hospital Erlangen, 91054, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Diakonissen Hospital Mannheim, 68163, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Ilka</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7109-2542</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Martin-Luther University Halle/Saale, 06120, Halle, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Sankt Georg, 04129, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7364-7791</Identifier><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, 18147, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Rostock/Greifswald, 18147, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metelmann</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8670-6148</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Leipzig, 04103, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohl</LastName><ForeName>Zacharias</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-4147-8866</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Regensburg, 93053, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linker</LastName><ForeName>Ralf A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-8740-3106</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Regensburg, 93053, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Jan Christoph</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-3778-0683</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Medicine G&#xf6;ttingen, 37075, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radelfahr</LastName><ForeName>Florentine</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-2805-4652</Identifier><AffiliationInfo><Affiliation>Friedrich-Baur-Institute, Department of Neurology, University Hospital, Ludwig Maximilian University of Munich, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;nfelder</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardt</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohajer-Peseschkian</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osmanovic</LastName><ForeName>Alma</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6012-8423</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Essener Zentrum F&#xfc;r Seltene Erkrankungen (EZSE), Universit&#xe4;tsmedizin Essen, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klopstock</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Friedrich-Baur-Institute, Department of Neurology, University Hospital, Ludwig Maximilian University of Munich, 80336, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 80336, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6352-0909</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, 89081, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-5401-0904</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, 89081, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;ffski</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-0048-0302</Identifier><AffiliationInfo><Affiliation>Chair of Health Management, School of Business, Economics and Society, Friedrich-Alexander University (FAU) Erlangen-N&#xfc;rnberg, 90403, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boentert</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6133-1397</Identifier><AffiliationInfo><Affiliation>Department of Neurology with the Institute of Translational Neurology, University Hospital M&#xfc;nster, 48149, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, UKM Marienhospital, 48565, Steinfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagenacker</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3631-3450</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Medicine Essen, 45147, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deschauer</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6116-6790</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts Der Isar, Technical University of Munich, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingor</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9362-7096</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts Der Isar, Technical University of Munich, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 80336, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9783-8584</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiber-Katz</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-5621-4487</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg Stra&#xdf;e 1, 30625, Hannover, Germany. dr.schreiber-katz@t-online.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cost of illness (COI)</Keyword><Keyword MajorTopicYN="N">Cost-utilities</Keyword><Keyword MajorTopicYN="N">Health-related Quality of Life (HRQoL)</Keyword><Keyword MajorTopicYN="N">Motor Neuron Disease (MND)</Keyword><Keyword MajorTopicYN="N">Quality-adjusted life years&#xa0;(QALYs)</Keyword><Keyword MajorTopicYN="N">Socio-economic burden</Keyword></KeywordList><CoiStatement>F. Heinrich reports no disclosures relevant to the manuscript. I. Cordts reports no disclosures relevant to the manuscript. R. G&#xfc;nther reports no disclosures relevant to the manuscript. B. Stolte received speaker honoraria from Biogen without relation to ALS. D. Zeller received compensation for participation on an advisory board of Biogen, as well as for consultancy work from Novartis. C. Schr&#xf6;ter reports no disclosures relevant to the manuscript. U. Weyen received compensation for activities with Merz and Desitin. M. Regensburger reports no disclosures relevant to the manuscript. J. Wolf reports no disclosures relevant to the manuscript. I. Schneider received personal/speaker fees from Sanofi-Genzyme, Biogen, and from the German Neuromuscular Society &#x201c;Deutsche Gesellschaft fuer Muskelkranke&#x201d; (DGM e.V.) without relation to ALS. A. Hermann received compensation for consultant work for Biogen, Desitin, and Roche. Additionally, A.&#xa0;Hermann received research funding from BMBF, GBA-Innovations Fund, Helmholtz Gesellschaft, NOMIS-Foundation, and &#x201c;Hermann und Lilly-Schilling Stiftung fuer medizinische Forschung&#x201d; im Stifterverband. M. Metelmann reports no disclosures relevant to the manuscript. Z. Kohl reports no disclosures relevant to the manuscript. R.A. Linker received compensation for activities with Biogen, Celgene, Merck, Novartis, and Roche, as well as research support from DFG, Else-Kroener-Fresenius Stiftung, Biogen, and Novartis. J.C. Koch received personal fees from Biogen, Roche, Avexis, Abbvie, and Ipsen, and funding by the &#x201c;Deutsche Gesellschaft fuer Muskelkranke&#x201d; (DGM e.V.) outside of the submitted work. F. Radelfahr reports no disclosures relevant to the manuscript. P. Schischlevskij reports no disclosures relevant to the manuscript. E. Sch&#xf6;nfelder reports no disclosures relevant to the manuscript. T. Mohajer-Peseschkian reports no disclosures relevant to the manuscript. A. Osmanovic received honoraria as a speaker/consultant from the German Neuromuscular Society &#x201c;Deutsche Gesellschaft fuer Muskelkranke&#x201d; (DGM e.V.), Biogen, and Impulze. T. Klopstock reports no disclosures relevant to the manuscript. J. Dorst reports no disclosures relevant to the manuscript. A.C. Ludolph received honoraria from Desitin, Novartis, Biogen, Roche, and the German Society of Neurology (Deutsche Gesellschaft fuer Neurologie e.V.). O.Sch&#xf6;ffski reports no disclosures relevant to the manuscript. M. Boentert received honoraria from UCB Pharma, Desitin, L&#xf6;wenstein Medical, Sanofi-Genzyme, and Biogen, as well as financial research support from Sanofi-Genzyme and L&#xf6;wenstein Medical. T.&#xa0;Hagenacker received honoraria from Biogen, Roche, Novartis, and Alexion without relation to ALS, and received research funding from Biogen, AveXis, and Roche without relation to ALS. M. Deschauer received personal fees as a speaker/consultant from Biogen, Roche, Sanofi-Genzyme, and Alnylam Pharmaceuticals. P. Lingor received honoraria from ITF-Pharma and Desitin with relation to ALS. S. Petri received honoraria as speaker/consultant from Biogen GmbH, Roche, Novartis, Teva, Cytokinetics Inc., Desitin, Italfarmaco, Amylyx, and Zambon; and grants from DGM e.V, Federal Ministry of Education and Research, German Israeli Foundation for Scientific Research and Development, EU Joint Program for Neurodegenerative Disease Research. O. Schreiber-Katz&#xa0;received honoraria as a speaker/consultant and/or funding for travel expenses from the German Neuromuscular Society &#x201c;Deutsche Gesellschaft fuer Muskelkranke&#x201d; (DGM e.V.), Novartis, Biogen GmbH, Biermann Verlag GmbH, and&#xa0;MK&#x2009;+&#x2009;S&#x2014;Medizin, Kommunikation &amp; Service GmbH.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>25</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>25</Day><Hour>14</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37356024</ArticleId><ArticleId IdType="pmc">PMC10511618</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11811-1</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11811-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Foster LA, Salajegheh MK. Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med. 2019;132:32&#x2013;37. doi: 10.1016/j.amjmed.2018.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2018.07.012</ArticleId><ArticleId IdType="pubmed">30075105</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Kim JE, Song TJ (2022) The global burden of motor neuron disease: an analysis of the 2019 global burden of disease study. Front Neurol 13:864339. 10.3389/fneur.2022.864339</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9068990</ArticleId><ArticleId IdType="pubmed">35528743</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nfelder E, Osmanovic A, M&#xfc;schen LH, Petri S, Schreiber-Katz O. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany. Orphanet J Rare Dis. 2020;15:149&#x2013;161. doi: 10.1186/s13023-020-01413-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-020-01413-9</ArticleId><ArticleId IdType="pmc">PMC7291655</ArticleId><ArticleId IdType="pubmed">32532288</ArticleId></ArticleIdList></Reference><Reference><Citation>Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, Walter MC, Nagels KH. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11(58):1&#x2013;9. doi: 10.1186/s13023-016-0424-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-016-0424-0</ArticleId><ArticleId IdType="pmc">PMC4857429</ArticleId><ArticleId IdType="pubmed">27145956</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, Habeeb-Louks EM, Kennedy A, Cwik VA. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49:431&#x2013;438. doi: 10.1002/mus.23942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23942</ArticleId><ArticleId IdType="pubmed">23836444</ArticleId></ArticleIdList></Reference><Reference><Citation>Murala S, Nagarajan E, Bollu PC. Hereditary spastic paraplegia. Neurol Sci. 2021;42:883&#x2013;894. doi: 10.1007/s10072-020-04981-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04981-7</ArticleId><ArticleId IdType="pubmed">33439395</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Qian Y, Sejersen T, Muntoni F, Wirth B, Tiziano FD, Kirschner J, Tizzano E, Topaloglu H, Swoboda K, Laing N, Kayoko S, Prior T, Chung WK, Wu S-M, Montes J, Mazzone E, Main M, Coleman C, Gee R, Glanzman A, Kroksmark A-K, Krosschell K, Nelson L, Rose K, St&#x119;pie&#x144; A, Vuillerot C, Vitale M, Snyder B, Quijano-Roy S, Dubousset J, Farrington D, Flynn J, Halanski M, Hasler C, Miladi L, Reilly C, Roye B, Sponseller P, Yazici M, Hurst R, Bertini E, Tarrant S, Barja S, Bertoli S, Crawford T, Foust K, Kyle B, Rodan L, Roper H, Seffrood E, Swoboda K, Szlagatys-Sidorkiewicz A. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103&#x2013;115. doi: 10.1016/j.nmd.2017.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2017.11.005</ArticleId><ArticleId IdType="pubmed">29290580</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Qian Y, Sejersen T. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197&#x2013;207. doi: 10.1016/j.nmd.2017.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2017.11.004</ArticleId><ArticleId IdType="pubmed">29305137</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2013;revised report of an EFNS task force. Eur J Neurol. 2012;19:360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy SM. Nusinersen: first global approval. Drugs. 2017;77:473&#x2013;479. doi: 10.1007/s40265-017-0711-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-017-0711-7</ArticleId><ArticleId IdType="pubmed">28229309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79:1255&#x2013;1262. doi: 10.1007/s40265-019-01162-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01162-5</ArticleId><ArticleId IdType="pubmed">31270752</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon S. Risdiplam: first approval. Drugs. 2020;80:1853&#x2013;1858. doi: 10.1007/s40265-020-01410-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01410-z</ArticleId><ArticleId IdType="pubmed">33044711</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919&#x2013;930. doi: 10.1056/nejmoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, Knowlton N, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson TD, Jackson C, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha SS, Miller TM, Scelsa SN, Vu TH, Fournier C, Johnson KM, Swenson A, Goyal N, Pattee GL, Babu S, Chase M, Dagostino D, Hall M, Kittle G, Eydinov M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Yu H, Cohen J, Klee J, Tanzi R, Gilbert W, Yeramian P, Cudkowicz M. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry. 2022;93:871&#x2013;875. doi: 10.1136/jnnp-2022-329024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-329024</ArticleId><ArticleId IdType="pmc">PMC9304116</ArticleId><ArticleId IdType="pubmed">35577511</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Clinical Excellence (2012) The guidelines manual. London. https://www.nice.org.uk/process/pmg6/resources/the-guidelines-manual-pdf-2007970804933. Accessed 02.10.2022</Citation></Reference><Reference><Citation>German Network for Motor Neuron Diseases (MND Net). http://www.mnd-als.de/html/home?set-language-to=en. Accessed 28.01.2021</Citation></Reference><Reference><Citation>Schorling E, Thiele S, Gumbert L, Krause S, Klug C, Schreiber-Katz O, Reilich P, Nagels K, Walter MC. Cost of illness in charcot-marie-tooth neuropathy: results from Germany. Neurology. 2019;92:e2027&#x2013;e2037. doi: 10.1212/wnl.0000000000007376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000007376</ArticleId><ArticleId IdType="pubmed">30918088</ArticleId></ArticleIdList></Reference><Reference><Citation>Peseschkian T, Cordts I, G&#xfc;nther R, Stolte B, Zeller D, Schr&#xf6;ter C, Weyen U, Regensburger M, Wolf J, Schneider I, Hermann A, Metelmann M, Kohl Z, Linker RA, Koch JC, B&#xfc;chner B, Weiland U, Sch&#xf6;nfelder E, Heinrich F, Osmanovic A, Klopstock T, Dorst J, Ludolph AC, Boentert M, Hagenacker T, Deschauer M, Lingor P, Petri S, Schreiber-Katz O. A nation-wide, multi-center study on the quality of life of ALS patients in Germany. Brain Sci. 2021;11:372&#x2013;396. doi: 10.3390/brainsci11030372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11030372</ArticleId><ArticleId IdType="pmc">PMC7998410</ArticleId><ArticleId IdType="pubmed">33799476</ArticleId></ArticleIdList></Reference><Reference><Citation>Schischlevskij P, Cordts I, G&#xfc;nther R, Stolte B, Zeller D, Schr&#xf6;ter C, Weyen U, Regensburger M, Wolf J, Schneider I, Hermann A, Metelmann M, Kohl Z, Linker RA, Koch JC, Stendel C, M&#xfc;schen LH, Osmanovic A, Binz C, Klopstock T, Dorst J, Ludolph AC, Boentert M, Hagenacker T, Deschauer M, Lingor P, Petri S, Schreiber-Katz O. Informal caregiving in amyotrophic lateral sclerosis (ALS): a high caregiver burden and drastic consequences on caregivers&#x2019; lives. Brain Sci. 2021;11:748. doi: 10.3390/brainsci11060748.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11060748</ArticleId><ArticleId IdType="pmc">PMC8228206</ArticleId><ArticleId IdType="pubmed">34200087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169:13&#x2013;21. doi: 10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847&#x2013;852. doi: 10.1093/brain/awr351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional rating scale. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration. 2014;15:279&#x2013;284. doi: 10.3109/21678421.2014.897357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.897357</ArticleId><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore A, Young CA, Hughes DA. Health Utilities and Costs for Motor Neurone Disease. Value in Health. 2019;22:1257&#x2013;1265. doi: 10.1016/j.jval.2019.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2019.05.011</ArticleId><ArticleId IdType="pubmed">31708062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundesministerium f&#xfc;r Gesundheit [Federal ministry of health] (2018) Online-Ratgeber Pflege. Pflegegrade [Online-guide care. Care levels]. Bundesministerium f&#xfc;r Gesundheit. https://www.bundesgesundheitsministerium.de/pflegegrade.html. Accessed Oct 12, 2020</Citation></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20:1727&#x2013;1736. doi: 10.1007/s11136-011-9903-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. Value Health. 2012;15:708&#x2013;715. doi: 10.1016/j.jval.2012.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2012.02.008</ArticleId><ArticleId IdType="pubmed">22867780</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495&#x2013;1499. doi: 10.1016/j.ijsu.2014.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2014.07.013</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, K&#xf6;nig HH. Calculation of standardised unit costs from a societal perspective for health economic evaluation. Gesundheitswesen. 2015;77:53&#x2013;61. doi: 10.1055/s-0034-1374621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1374621</ArticleId><ArticleId IdType="pubmed">25025287</ArticleId></ArticleIdList></Reference><Reference><Citation>Institut f&#xfc;r Qualit&#xe4;t und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care] (2020) Allgemeine Methoden [General methods]. Colone, Germany. https://www.iqwig.de/methoden/allgemeine-methoden-v6-1.pdf. Accessed 13.02.2021</Citation></Reference><Reference><Citation>Statistisches Bundesamt [Federal Statistical Office of Germany] (2020) Verbraucherpreisindizies - Gesamtindex und 12 Abteilungen [Consumers' price index - full index and 12 figures]. destatis Statistisches Bundesamt. https://www.destatis.de/DE/Themen/Wirtschaft/Preise/Verbraucherpreisindex/Tabellen/Verbraucherpreise-12Kategorien.html. Accessed 13.01.2021</Citation></Reference><Reference><Citation>Icks A, Chernyak N, Bestehorn K, Bruggenjurgen B, Bruns J, Damm O, Dintsios CM, Dreinhofer K, Gandjour A, Gerber A, Greiner W, Hermanek P, Hessel F, Heymann R, Huppertz E, Jacke C, Kachele H, Kilian R, Klingenberger D, Kolominsky-Rabas P, Kramer H, Krauth C, Lungen M, Neumann T, Porzsolt F, Prenzler A, Pueschner F, Riedel R, Ruther A, Salize HJ, Scharnetzky E, Schwerd W, Selbmann HK, Siebert H, Stengel D, Stock S, Voller H, Wasem J, Schrappe M. Methods of health economic evaluation for health services research. Gesundheitswesen. 2010;72:917&#x2013;933. doi: 10.1055/s-0030-1262859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0030-1262859</ArticleId><ArticleId IdType="pubmed">20865653</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistisches Bundesamt [Federal Statistical Office of Germany] (2021) Einkommen, Einnahmen und Ausgaben in den Gebietsst&#xe4;nden [Income, revenues and expenditures in the administration units]. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Einkommen-Konsum-Lebensbedingungen/Einkommen-Einnahmen-Ausgaben/Tabellen/liste-gebietsstaende.html;jsessionid=F71FE5CAC7DB3D3B07816AA772FA4269.internet722. Accessed 01.02.2021</Citation></Reference><Reference><Citation>Deutsche Bundesbank [Federal Bank of Germany] (2021) Zeitreihe BBEX3.A.USD.EUR.BB.AC.A04: Euro-Referenzkurs der EZB / 1 EUR = ... USD / Vereinigte Staaten [Time series BBEX3.A.USD.EUR.BB.AC.A04: Euro reference course of the European central bank / 1 EUR =...USD / United States of America]. Deutsche Bundesbank Eurosystem. https://www.bundesbank.de/dynamic/action/de/statistiken/zeitreihen-datenbanken/zeitreihen-datenbank/723452/723452?listId=www_s331_b01012_1&amp;tsTab=0&amp;tsId=BBEX3.A.USD.EUR.BB.AC.A04&amp;id=0. Accessed 28.01.2021</Citation></Reference><Reference><Citation>Sch&#xf6;ffski O, Schulenburg J-M. Gesundheits&#xf6;konomische evaluationen [Health Economics Evaluations] Berlin: Springer; 2012.</Citation></Reference><Reference><Citation>Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, Forsmark A, Vickers AD, Lloyd A. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019;37:845&#x2013;865. doi: 10.1007/s40273-019-00769-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-019-00769-6</ArticleId><ArticleId IdType="pubmed">30714083</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistisches Bundesamt [Federal Office of Statistics] (2020) Sterbetafel 2017/2019&#x2014;Ergebnisse aus der laufenden Berechnung von Periodensterbetafeln f&#xfc;r Deutschland und die Bundesl&#xe4;nder [Mortality tables 2017/2019). Wiesbaden. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Sterbefaelle-Lebenserwartung/Publikationen/Downloads-Sterbefaelle/periodensterbetafel-erlaeuterung-5126203197004.pdf?__blob=publicationFile. Accessed 02.10.2022</Citation></Reference><Reference><Citation>Acsadi G, Crawford TO, M&#xfc;ller&#x2010;Felber W, Shieh PB, Richardson R, Natarajan N, Castro D, Ramirez&#x2010;Schrempp D, Gambino G, Sun P, Farwell W (2021) Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study. Muscle &amp; Nerve:1&#x2013;10. 10.1002/mus.27187</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248061</ArticleId><ArticleId IdType="pubmed">33501671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol. 2013;126:307&#x2013;328. doi: 10.1007/s00401-013-1115-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1115-8</ArticleId><ArticleId IdType="pmc">PMC4045499</ArticleId><ArticleId IdType="pubmed">23897027</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119. doi: 10.1056/nejmoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistisches Bundesamt [Federal Statistical Office of Germany] (2020) Pressemitteilung Nr. 223 vom 19. Juni 2020 [Press announcement no. 223]. https://www.destatis.de/DE/Presse/Pressemitteilungen/2020/06/PD20_223_12411.html. Accessed 31.03.2021</Citation></Reference><Reference><Citation>Rosenbohm A, Peter RS, Erhardt S, Lul&#xe9; D, Rothenbacher D, Ludolph AC, Nagel G. Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol. 2017;264:749&#x2013;757. doi: 10.1007/s00415-017-8413-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8413-3</ArticleId><ArticleId IdType="pubmed">28220290</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, Cook SF, Lochm&#xfc;ller H (2017) Prevalence, incidence and carrier frequency of 5q&#x2013;linked spinal muscular atrophy&#x2014;a literature review. Orphanet Journal of Rare Diseases 12:124: . 10.1186/s13023-017-0671-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496354</ArticleId><ArticleId IdType="pubmed">28676062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42:174&#x2013;183. doi: 10.1159/000358801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000358801</ArticleId><ArticleId IdType="pubmed">24603320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q-Q, Hou Y, Chen Y, Ou R, Cao B, Zhang L, Yang T, Shang H (2021) Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L. Health and Quality of Life Outcomes 19:181: . 10.1186/s12955-021-01822-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8290546</ArticleId><ArticleId IdType="pubmed">34284776</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Sieniawski M, Kollewe K, Rath KJ, Krampfl K, Zapf A, Dengler R, Petri S. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:20&#x2013;25. doi: 10.3109/17482968.2012.692382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.692382</ArticleId><ArticleId IdType="pubmed">22871079</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Wiesner T, Malone DC, Bischof M, Toro W, Dabbous O. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma&#xae;) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER) Journal of Market Access &amp; Health Policy. 2021;9:1889841. doi: 10.1080/20016689.2021.1889841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20016689.2021.1889841</ArticleId><ArticleId IdType="pmc">PMC7919869</ArticleId><ArticleId IdType="pubmed">33708361</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan HJ, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, Maturi B, Klein-Panneton K, Cabalteja C, Lochm&#xfc;ller H. Burden of Spinal Muscular Atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021;8:553&#x2013;568. doi: 10.3233/jnd-200610.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jnd-200610</ArticleId><ArticleId IdType="pmc">PMC8385498</ArticleId><ArticleId IdType="pubmed">33749617</ArticleId></ArticleIdList></Reference><Reference><Citation>Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA community update survey. Orphanet J Rare Dis. 2020;15(217):1&#x2013;11. doi: 10.1186/s13023-020-01498-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-020-01498-2</ArticleId><ArticleId IdType="pmc">PMC7447573</ArticleId><ArticleId IdType="pubmed">32838797</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Paganoni S, Braastad C, Cudkowicz M, Atassi N. Disease burden in upper motor neuron syndromes. J Clin Neuromuscul Dis. 2014;16:104&#x2013;105. doi: 10.1097/cnd.0000000000000051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/cnd.0000000000000051</ArticleId><ArticleId IdType="pmc">PMC4243581</ArticleId><ArticleId IdType="pubmed">25415523</ArticleId></ArticleIdList></Reference><Reference><Citation>De Souza PVS, De Rezende Pinto WBV, De Rezende Batistella GN, Bortholin T, Oliveira ASB. Hereditary spastic paraplegia: clinical and genetic hallmarks. The Cerebellum. 2017;16:525&#x2013;551. doi: 10.1007/s12311-016-0803-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12311-016-0803-z</ArticleId><ArticleId IdType="pubmed">27271711</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimpe S, Sch&#xfc;le R, Kassubek J, Otto S, Kohl Z, Klebe S, Klopstock T, Ratzka S, Karle K, Sch&#xf6;ls L (2012) Disease severity affects quality of life of hereditary spastic paraplegia patients. European Journal of Neurology 19:168&#x2013;171. 10.1111/j.1468-1331.2011.03443.x</Citation><ArticleIdList><ArticleId IdType="pubmed">21631647</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, Nagels KH, Walter MC. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210&#x2013;223. doi: 10.1186/s13023-014-0210-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-014-0210-9</ArticleId><ArticleId IdType="pmc">PMC4302713</ArticleId><ArticleId IdType="pubmed">25519771</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzstein M, Rommel A, Lange C (2015) Informal caregivers - Germany&#x2019;s largest nursing service. GBE kompakt 6:1&#x2013;11. 10.17886/RKI-GBE-2016-002</Citation></Reference><Reference><Citation>Aranda-Reneo I, Pe&#xf1;a-Longobardo LM, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano EF, L&#xf3;pez-Bastida J. The burden of spinal muscular atrophy on informal caregivers. Int J Environ Res Public Health. 2020;17:8989. doi: 10.3390/ijerph17238989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17238989</ArticleId><ArticleId IdType="pmc">PMC7730048</ArticleId><ArticleId IdType="pubmed">33276656</ArticleId></ArticleIdList></Reference><Reference><Citation>Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH (2020) Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Effectiveness and Resource Allocation 18:41: . 10.1186/s12962-020-00234-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539471</ArticleId><ArticleId IdType="pubmed">33041673</ArticleId></ArticleIdList></Reference><Reference><Citation>Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B. Empirical standard costs for health economic evaluation in Germany&#x2014;a proposal by the working group methods in health economic evaluation. Gesundheitswesen. 2005;67:736&#x2013;746. doi: 10.1055/s-2005-858698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2005-858698</ArticleId><ArticleId IdType="pubmed">16235143</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>